For newly diagnosed AML with FLT3 mutations, it has become standard to add midostaurin (dosage 50 mg q12h PO d8–21) to induction therapy in which the foundation is composed of anthracyclines (e.g., daunorubicin, idarubicin) and cytarabine in the “7+3” scheme. Here, FLT3 is linked to acute myeloid leukemia.